Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 344-349

  Feng, Ji feng ^a,b   Wu, Jian zhong ^b   Hu, Sai nan ^b   Gao, Chang ming ^b   Shi, Mei qi ^b   Lu, Zhu hong ^a   Sun, Xin chen ^a   Zhou, Jin Rong ^c   Chen, Bao an ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Genetic polymorphism; Non small cell lung cancer; Platinum; RRM1

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYSTEINE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GENOMIC DNA; IFOSFAMIDE; NAVELBINE; OXALIPLATIN; PLATINUM COMPLEX; PRALITAXEL; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1 PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 70350619498     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.015     Document Type: Article

References (18)

1. Rosell R., Lord R.V., Taron M., and Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38 (2002) 217-227
2. Rosell R., Taron M., and O'Brate A. Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol 13 (2001) 101-109
3. Garcia-Campelo R., Alonso-Curbera G., Anton Aparicio L.M., and Rosell R. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother 6 (2005) 2015-2026
4. Bepler G., Gautam A., McIntyre L.M., et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20 (2002) 1353-1360
5. Bepler G., Zheng Z., Gautam A., et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47 (2005) 183-192
6. Kim S.O., Jeong J.Y., Kim M.R., et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 14 (2008) 3083-3088
7. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
8. Gautam A., and Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66 (2006) 6497-6502
9. Zheng Z., Chen T., Li X., Haura E., Sharma A., and Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
10. Bepler G., Sharma S., Cantor A., et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 1878-1885
11. Ceppi P., Volante M., Novello S., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
12. Souglakos J., Boukovinas I., Taron M., et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98 (2008) 1710-1715
13. Smid K., Bergman A.M., Eijk P.P., et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids 25 (2006) 1001-1007
14. Butkiewicz D., Rusin M., Enewold L., Shields P.G., Chorazy M., and Harris C.C. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 22 (2001) 593-597
15. Ronen A., and Glickman B.W. Human DNA repair genes. Environ Mol Mutagen 37 (2001) 241-283
16. Isla D., Sarries C., Rosell R., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15 (2004) 1194-1203
17. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 2741-2746
18. Simon G.R., Ismail-Khan R., and Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39 (2007) 1318-1328